latest strategic consulting presentation

25
September 2014 Realizing Possibilities, Together Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com

Upload: aagami-inc

Post on 29-Nov-2014

5.420 views

Category:

Business


0 download

DESCRIPTION

 

TRANSCRIPT

Page 1: Latest Strategic Consulting Presentation

September 2014

Realizing Possibilities, Together

Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com

Page 2: Latest Strategic Consulting Presentation

Lifesciences Catalyst2

Aagami, Inc.

A life sciences consulting firm based in the suburbs of Chicago offers

For Global Biotech, Pharmaceutical , Medical Devices and Consumer Health products companies, in their initiatives with India, Asia and Emerging Markets.

Strategic Consulting ServicesTechnology Licensing ServicesBusiness & Market Research Services

Page 3: Latest Strategic Consulting Presentation

Lifesciences Catalyst3

Strategic Consulting Services

In-Licensing or Out-Licensing

Co-Development and Partnerships

Investments to and from India/Asia

Mergers & Acquisitions

Finding the Right Partners

JV and/or Distributors

CRO and CRAMS providers

Contract Sales/Marketing

Contract Manufacturing

Page 4: Latest Strategic Consulting Presentation

Offerings in Market/ Business Research

Competitive Landscape Assessments

Analysis of Portfolio and Opportunities identification

Price Discovery Research

Due Diligence

IP and Regulatory Research

Financial Modeling, NPV valuations

New Market Entry strategy

Market development strategy

4 Lifesciences Catalyst

Page 5: Latest Strategic Consulting Presentation

Lifesciences Catalyst5

Aagami brings

Deep Understanding of business and socio-cultural differences in ways of working

Extensive network with Top LifeSciences companies at CXO levels

Global Deal experience mainly with Western, Japanese and Indian industry

Aagami Partners bring value of combined experience of over 120 years.

Focus on your needs, objectives, success and work as an extension of your team.

Page 6: Latest Strategic Consulting Presentation

Lifesciences Catalyst6

Strategy

SectorIN Licensing

OUT

LicensingM & A

Partnership

Co-DevelopmentRegulatory

Market

Research

& Entry

Supply Chain &

DistributionBD

Pharmaceuticals

Biotechnology

CRO & CRAMS

Delivery Technology

Diagnostics

Consumer Health Products

Nutraceuticals/

Cosmeceuticals

Medical Device

Labware

Supported all Business Sectors

The colored boxes represent our experience in that Sector and Strategic area

Page 7: Latest Strategic Consulting Presentation

Lifesciences Catalyst7

Sample list of Successes (Also see Case Studies for more details)

Licensing and Co-Development partnership for Novel Protein Therapeutic Platform of a German company; Deals done with 2 Major Pharma

Licensing of a dermal delivery system of an Australian company, applicable to both pharmaceutical and personal care products. Licensing Deals signed with 3 companies; Product launched with one; A few more deals in discussion.

Finding customers for Peptides API for a EU conglomerate. Orders received from 8 companies, Few others in final discussions.

Out-Licensing & Distribution partnerships for an Ophthalmic Medical Device company. Signed with a major Pharma Company.

Creation and management of MSDS for a Fortune 100 Chemical company from Midwest US by striking alliance with the right partner in India. 85% Cost reduction was achieved within 6 months of starting operation.

Page 8: Latest Strategic Consulting Presentation

8

Sample list of Aagami Clients

USA

CreAgri CA

New Heaven Pharma CT

Advangene IL

Loyola Univ. Chicago IL

OncBioMune LA

Dow Chemicals MI

ScyFIX MN

Penwest Corp. NY

DesignMedix OR

PLx TX

InternationalPhosphagenics Australia

PeptiSyntha Belgium

DelMar Pharma Canada

Affitech Denmark

Pieris Germany

Merus Holland

Venus Remedies India

Opsona Ireland

Toppan Japan

Otago University New Zealand

Lifesciences Catalyst

Aagami has completed over 100 assignments for more than 50 clients in the last 11+ years.

Page 9: Latest Strategic Consulting Presentation

Lifesciences Catalyst9

Sample of Aagami contacts in India

We are connected at CXO Level of TOP 100 Lifesciences companies in India. Some of the popular names are below.

Biocon Intas Sun PharmaCadila Lupin ThemisCipla MicroLabs Torrent PharmaDr Reddys Piramal USVGlenmark Reliance WockhardtHetero Drugs Strides Zydus

Page 10: Latest Strategic Consulting Presentation

Lifesciences Catalyst10

Our Consulting Approach

Setup

• Understand and capture important details about the asset/technology

• Prepare ‘Elevator Pitch’ (EP) customized to specific business culture

• Identify relevant companies from our database and resources

Prospect

• Broadcast EP to Relevant Companies

• Follow-up with phone calls and emails

• Coordinate CDAs with interested Companies

• Supply further info through emails

• Organize conference calls for clarifications

Finalize

• Organize Road show

• Manage appointments with right executives

• Coordinate the logistics of the road show

• Advise on structuring the deal

• Support in negotiations (most critical)

Page 11: Latest Strategic Consulting Presentation

Lifesciences Catalyst11

Consulting Engagement Model

Dedicated Teamwork (40-80 Hours/month)

Small binding fee for first 6 months

Success fee based on the modified Lehman’s formula

Aagami’s prime focus is CLIENT SUCCESS as that's how we Succeed

Page 12: Latest Strategic Consulting Presentation

Research Approach

Study/ Research

• Primary

• Interviews with different stakeholders in the Value chain including opinion leaders, vendors and customers

• Proceedings of Industry events, press conferences and workshops

• Surveys /studies

• Secondary

• Company websites, social media, blogs, forums and groups

• Business directories and databases

• Online and offline libraries and government data

• Economic and Demographic information, Census

• Case studies, Reference Customers, vendors, and associations

Analysis

• Qualitative

• Policy and Regulatory environment

• Competitive Landscape Assessment (CLA)

• Business Analysis, Industry Analysis

• Trends & Drivers,

• Challenges and Risks

• Quantitative

• Market Sizing, Segmentation and Forecasting

• Market share and Opportunity Analysis

Reporting

• Deliverables

• Whitepapers

• Industry Reports

• Investment Models

• Trend Reports

• Tracking Reports

• Competitive Report

• Price Discovery Report

• Corporate Profiles

• Forecasts

• Guesstimates

• NPV Valuation

• Client Presentation and clarifications on client questions

Assess, Analyze, Derive, Synthesize, Report

24-Sep-1412 Lifesciences Catalyst

Page 13: Latest Strategic Consulting Presentation

Research Engagement Models

Need Based

Suits Adhoc and one-off Requirements.

e.g. New Product or Market Entry research, suspect and prospect identification, partner

identification, IP Landscape

Dedicated Teams

Suits regular research needs at low operating

costs

e.g. Need dedicated support teams for core business or corporate

teams

Multi-client studies

Most suitable for multiple clients with

common requirements and shared costing

e.g. industry research by association

24-Sep-14Lifesciences Catalyst13

Custom engagement models can also be discussed

Page 14: Latest Strategic Consulting Presentation

Lifesciences Catalyst14

Aagami Leadership Team

Dinesh Jain - Founder CEO

• A business leader in Science and technology industry since 1984 with global experience in starting and managing several technology companies. Has held positions of CEO, President, Vice President. Is a prolific entrepreneur. Has executed severaldozen international deals across 4 continents. He is a regular speaker in International conference son Life Sciences Businesswith India, and also on board of several consulting and research companies

Dr. Mahendra Shah – Company Advisor

• A veteran Scientific leader in Bio-Pharmaceutical field since 1968 . After his PhD, he has worked with some of the top notch companies like Bristol, Squibb, Schering, Lyphomed, Fujisawa, EJ Financials, First Horizon, NextWave. Mahendra is an active Investor in BioPharmaceutical field and is on the Board of several companies across the country.

Dr. Shridhar Andurkar – Scientific Advisor

• Chair and Associate Professor of Pharmaceutical sciences at Midwestern University, Chicago College of Pharmacy, is a Ph D from Auburn University in Medicinal Chemistry, Conducted postdoctoral research at the University of Houston. Dr. Andurkar has published numerous papers and made several presentations in this field. He holds a US patent in the area of anticonvulsant drugs and is on the advisory boards of several companies.

Nancy Chew - Regulatory Advisor

• A serial entrepreneur, veteran business leader, biochemist and Pharmacologist by education, Regulatory expert, Several top honors & award winner and Advisor to numerous Life Sciences companies.

• Nancy's accomplishments and achievements of over 39 years would take several pages to detail.

Page 15: Latest Strategic Consulting Presentation

Lifesciences Catalyst15

Aagami Associate Partners Dr. Hemant Sabharwal M.D., Ph.D. – Founder - Laktobiotics

• 15 years of extensive global experience in the Academia and Pharma Industry. Lived and worked in the Middle East, Egypt, Scandinavia, India, and the US. He is also Adjunct Faculty in Department of Medical Microbiology and Immunology, Streptococcal vaccine development, Rockefeller University, New York, NY. To his credit, he has more than 20 publications in peer reviewed Medical and Scientific journals. In the past, he has worked with prestigious institutions such as Institute for Cancer Prevention, NY, Mount Sinai Medical Center, NY, Lund University, Sweden, MonoCarb AB, Sweden, BioCarb AB, Sweden

Anant Kataria – Founder Partner, Sagacious Research• Anant's expertise lies in supporting Patent Practitioners/Consultants, Patent Licensing Firms/Executives, Law firms

in US and Europe by providing a cost-effective back-end team for all their patent related needs. His past work experience is a blend of Intellectual Property Research (IP) in various technical domains and R&D in Automobile Industry.

Vyom Shah, Founder, Phronesis Strategies• Vyom has worked with companies such as PwC and TCS. With 9+ years of experience, he has extensively worked

on several consulting and research cases including NPV valuations across diverse verticals and has served clients ranging from Fortune 500 companies to SMEs, supporting end-to-end engagement lifecycle. He holds an MBA from Lancaster University Management School, UK, specialising in Strategy and Management Consulting and is a qualified Chartered Accountant.

Faiz Wahid - Co-founder, pManifold Research and Consulting• Faiz started pManifold in 2010 focusing on research, consulting and stakeholder engagement services. Under his

leadership the firm has conducted over 10000+ primary customer interviews for various cross sector companies. He holds an MBA from HEC Paris and was an international scholar at the Darden School of Business of the University of Virginia. He also holds a masters in engineering from BITS Pilani and bachelors in engineering from VNIT Nagpur.

Page 16: Latest Strategic Consulting Presentation

Lifesciences Catalyst16

USA (Head Office)

Aagami, Inc. 2135 City Gate Lane Suite 300

Naperville, IL 60653

P: +1-630-364-1837

INDIA

Aagami

741, Nelson Square

Nagpur MH 440013

P: +91-712-258-6678

Dinesh Jain

Email: [email protected]

M: +1 630-853-3520

Godwyn Francis

Email: [email protected]

M: +91-787-501-6957

www.aagami.com

CONTACT

© Aagami, Inc. 2014 | All rights reserved

Page 17: Latest Strategic Consulting Presentation

Select Case Studies

Strategic Consulting

Business and Market Research

Lifesciences Catalyst17

Page 18: Latest Strategic Consulting Presentation

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Establishing Partnerships for Development and Commercialisation of Novel Class of Protein Drugs

Innovator partners in India to collaborate on a new class of proteins -Anticalins® to develop various programs in Oncology and Ophthalmology.

18

German Biotech company making safer, effective and differentiated Novel drugs

Aagami identified right partners, and took them to 7 interested companies for Anticalins®

With focused efforts 3 companies moved to term sheet level discussions. Aagami kept facilitating and persevering. 2 companies remained for final negotiations.

Aagami maintained its spirits and perseverance knowing Indian ways of working; even when client was ready to give up as per Western ways.

Finally co development partnership happened in next few months with one company in Oncology.

Second company took more time and couple of visits before signing co-development deal for ophthalmic therapy.

Client signed co-development deals with 2 companies in Oct and Dec2013 respectively

Right companies, right advice, structure, perseverance and commitment were the key success factor. in making it happen.

Aagami proved highly influential in negotiations for finalization of the deals due to deep experience in business culture nuances of India.

It brought repeat and referral business to Aagami.

Lifesciences Catalyst

Page 19: Latest Strategic Consulting Presentation

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Technology Out-licensing of Transdermal Drug Delivery Technology with 3 Indian Companies

To Out-License TPM® Technology and Co-Develop in clinic products using proprietary Delivery technology and market such products in India and possibly larger region.

19

TPM® Technology and Products Company from Australia

Aagami scanned numerous companies and got 10 relevant companies interested.

Discussion with 8 companies progressed.

Took client to India 3 times for term sheet level meetings and deal signing.

Facilitated entire evaluation and deal structuring process

Aagami made sure testing and other protocols were honoured before deal was made.

During the process Aagami ensured clear understanding despite socio cultural differences in styles of working.

Deals with 3 global companies of India

The first deal was struck for diclofenac topical gel formulation containing TPM platform. The Indian partner not only launched their own product but also out licensed to a major western pharma.

The second alliance was struck for use in Skin Whitening and under eye cream.

Third deal - Aagami was able to facilitate a new business model with this prospect, who using client technology increased bio availability as well as stability of a specific antibiotic.

Lifesciences Catalyst

Page 20: Latest Strategic Consulting Presentation

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Exclusive Worldwide Licensing for a Fragrance and Flavors Technology

The University developed an improved process to make Safranal faster, cheaper, and greener.

After patenting it they were finding it difficult to out license it even after more than 2 years of trying .

20

Technology Licensing Office of a reputed University from Chicago area

Aagami deployed a senior consultant to understand and capture important details about the asset / technology

Identified relevant companies in India and elsewhere.

Shortlisted 68 companies and sent them customized ‘Elevator Pitch’ (EP)

After several follow ups on phone calls and emails, coordinated CDAs and conference calls with several interested Companies and brought 3 companies on term sheet level discussions

Aagami supported in structuring and negotiating the deal discussions.

Finally established the partnership within 6 months from the start date

Technology licensing partnerships made with 2 companies in India in 6 months

Client said: “It takes a lot of time and people to pull off an agreement like this, ….. we’re very pleased that we were able to align ourselves with these two reputable international companies.”

http://loyolastudentdispatch.com/2010/11/05/loyola-flavor-and-fragrance-research-goes-global/

Lifesciences Catalyst

Page 21: Latest Strategic Consulting Presentation

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Licensing and Distribution of an Innovative Ophthalmic Device for Dry ARMD and RP in India

Finding Right partner for Indian market of their innovative micro-current based Ophthalmic Medical Device.

The device prevents progression of dry ARMD (Age Related Macular Degeneration) and Retinitis Pigmentosa

21

Innovative Medical Device company from Minnesota

A Distribution Partnership established with a Top Tier Pharma company specializing in Ophthalmic market

Aagami first understood and captured the important details about the asset and the technology

Identified Ophthalmic focused companies in India to invest in and distribute client product.

Shortlisted 9 companies, both investors and distributors and sent them customized ‘Elevator Pitch’ (EP)

After follow ups, CDAs and conference calls with interested parties Aagami organized a Road-Show to India with top management of client firm

Aagami supported in structuring and negotiating the deal discussions.

Successfully established the distribution relationship

Lifesciences Catalyst

Page 22: Latest Strategic Consulting Presentation

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Reducing cost of creation and management of MSDS

Cost reduction for customized MSDS for various countries with unique regulations for thousands of chemicals it produces.

22

Fortune 100 Chemical company from Midwest US

Client is in Chemicals business for over 100 years across 150 countries and needed to create 1000s of MSDS every month.

This had become very expensive due to complexities and different regulatory needs of various countries .

Aagami analysed the situation and suggested offloading such processes to Indian companies

Aagami scanned though its database and network to identify the right partners.

Performed due diligence on the shortlisted agencies and facilitated discussions and influenced negotiations and deal structuring

Aagami helped strike alliance with the right partner in India.

85% Cost reduction was achieved within 6 months of starting operation

The client continues to employ Global Delivery Model for MSDS creation and management

Lifesciences Catalyst

Page 23: Latest Strategic Consulting Presentation

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Study of Market Potential and Prospective Partners in India for hand-held qPCR Diagnostic Device

A mobile, lightweight molecular diagnostic technology and device was developed at the University. Its Innovation center wanted to study the market potential in India.

As per Aagami’s suggestion, client agreed to include regulatory overview and potential partners in the study.

23

Innovation Center of a New Zealand University focused on Health Sciences

Aagami involved a team of a senior and a junior researcher to conduct secondary and primary research to assess and collect market data.

Identified Competitors and their product ranges and also did a brief comparison analysis.

Prepared a crisp and concise report with data, analysis and recommendations

Also prepared a regulatory overview document

Captured the potential end users of the product as well as shortlisted potential partners

Offered consulting support for Partnership Development and India Market Entry with a clearly defined Partnering Strategy and roadmap to achieve the goal.

The report helped the University in determining conclusively on India market initiative.

Pleased with the report, the University appointed Aagami to find a licensing partner in India

Lifesciences Catalyst

Page 24: Latest Strategic Consulting Presentation

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Global NPV of Technology (in USD Million)

(P) Pessimistic Scenario

Discount rate 8.60%

Year 2012 2013 2014 2015 2016 2017 2018

Time 0 1 2 3 4 5 6

Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93

Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19

Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98

Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57

Commercialisation Costs 400.00 - - - - - -

Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11

Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55

Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56

Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61

Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44

NPV 1,524.77

Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform

Client wanted to commercialize ground breaking technology in the MI Diagnostics field, and wanted to know its commercial potential so that suitable licensing fees and model could be determined and also value could be showcased to Licensees

24

Investors Controlled Innovative technology company

Aagami involved a team of a senior consultant part time and a business analyst full time to conduct primary and secondary research involving domain specialists to capture current market scenario.

Performed competitive benchmarking to assess a Relative Cost Benefit Index used later for determining technology platform (product) pricing.

Projected annual demand for next ten years in three different scenarios -Median, Optimistic and Pessimistic across multiple disease categories.

Forecasted Global Average Selling Price (ASP) and Cost associated with capex and opex

Validated commercializing options and measured incremental financial scenario for potential licensees

Determined the Global Net Present Value (NPV) and created Financial models

NPV of the technology and indicative licensing fees, along with several insights generated, served as conclusive guidance to the client for deal-making and negotiations.

The client was delighted which also resulted in repeat assignments

Lifesciences Catalyst

Page 25: Latest Strategic Consulting Presentation

CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Competitive Landscape Analysis in India to finalize Pricing strategy of high-end Cosmeceuticals

Client, a public limited company in Australia needed to get a competitive landscape of prestige skin whitening, anti-ageing and body shaping market in India, to order to device strategy on their pricing and licensing for Indian Market

25

Publicly Listed Australian skincare products & technology company

Aagami involved a team of a senior and a junior researcher part time to conduct secondary research on web and primary research via in person visits to shops, mall and interviews with Industry professionals, Business owners, store managers, salon managers and doctors to assess market and collect data

Identified Competitors and their product ranges with their Price points and feedback from stakeholders

Prepared a crisp and concise report with data, analysis and Unit Price Map in MS- Excel format in an easy to understand and customized views.

Performed competitive benchmarking to assess a Relative Cost Benefit Index and recommended potential product pricing ranges.

As per client, the report was extremely helpful and enlightening in preparing for their trip to India, and proved essential in determining conclusively whether their product range is capable of selling in the Indian market at the equivalent of Australian retail prices

Lifesciences Catalyst